HANSA BIOPHARMA

Søren Tulstrup,
President & CEO

Hitto Kaufmann,
Chief R&D Officer

27 May 2024



Broad clinical pipeline in transplantation, autoimmune diseases, and gene therapy

Project	Indication	Research/ Preclinical	Phase 1	Phase 2	Phase 3	Marketing Authorization	Marketed	Partner	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients[1,2]								EU: Additional agreements around reimbursement / Post approval study to be completed by 2025
	U.S. "ConfIdeS": Kidney transplantation in highly sensitized patients[1,2]								Completion of randomization (64 patients) mid 2024
	GOOD-IDES-02: Anti-GBM antibody disease								Complete enrollment (50 patients)
	16-HMedIdes-12: Active Antibody Mediated Rejection (AMR)								Publication in peer-reviewed journal
	15-HMedIdeS-09: Guillain-Barré Syndrome (GBS)								Comparative efficacy analysis 2024
	Investigator-initiated trial in ANCA-associated vasculitis[3]								Complete enrollment (10 patients)
	SRP-9001-104: Pre-treatment ahead of gene therapy in Duchenne Muscular Dystrophy (DMD)		Phase 1b					**Sarepta Therapeutics**	Completion of enrollment
	Pre-treatment ahead of gene therapy in Limb-Girdle Muscular Dystrophy (LGMD)							**Sarepta Therapeutics**	Preclinical research
	Pre-treatment ahead of gene therapy in Pompe disease							**AskBio**	Preclinical research
	Pre-treatment ahead of gene therapy in Crigler-Najjar syndrome							**Genethon**	Commence clinical study
HNSA-5487	NICE-01 phase 1: HNSA-5487 – Lead candidate from the NiceR program								Further analysis around endpoints from Phase 1 to be completed in 2024 incl. selection of lead indication

Completed | Ongoing | Planned | Post approval study running in parallel with commercial launch

[1] Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
[2] Lorant et al., American Journal of Transplantation and 03+04 studies (Jordan et al., New England Journal of Medicine)
[3] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

Hansa Biopharma – a biotech to believe in

Commercial stage, science driven biotechnology company in Sweden with financing into 2026

At a glance

2007	160	$250M	$34.6M
founded in Lund, Sweden	employees globally	market cap	recent financing round

Purpose driven culture

33	4th year	18%
different nationalities	Great Place to Work® certified	reduction in energy consumption*

Proprietary technology platform

Autoimmune

Gene Therapy

Transplantation

Portfolio

IMLIFIDASE
1st in class IgG cleaving molecule

HNSA-5487
Next-gen IgG cleaving molecule

Pipeline

Two Phase 1
- ✓ 5487 FIH, DMD gene therapy

Three Phase 2
- ✓ AMR, GBS, ANCA (IIT)

Three Phase 3
- ✓ US kidney, EU post approval, anti-GBM

*According to 2023 Sustainability Report

Imlifidase is an innovative, first in class molecule with a novel approach to eliminate pathogenic IgG

Originates from a bacteria
Streptococcus pyogenes known from causing a strep throat infection

IgG antibody-cleaving enzyme
Interacts with Fc-part of IgG with extremely high specificity

Inactivates IgG in 2-6 hours
Rapid onset of action that inactivates IgG below detectable level in 2-6 hours

Unique MOA cleaves IgG creating an IgG free window for approximately one week



7 clinical trials in key disease areas

- **Autoimmune**
- **Gene Therapy**
- **Transplantation**

First & only treatment approved for desensitization

EU Approval**
in kidney TX as IDEFIRIX®

75%
access in the EU transplant market

2025
planned US BLA filing; US trial ongoing

*The 5-year data is a continuation of the analysis at 3-years of crossmatch positive patients published in the *American Journal of Transplantation*

**IDEFIRIX approved in EEA under conditional approval for kidney transplantation

Transplantation



Imlifidase may enable incompatible kidney transplantation in highly sensitized patients

80-100k
patients waiting for a kidney transplant

DSAs
Donor specific antibodies that reject organ transplantation

SOC
based on organ compatibility

10-15%
patients with donor specific antibodies (DSAs) or highly sensitized - unlikely to be transplanted due to incompatibility

Long term data in kidney transplantation confirms sustained benefit of imlifidase



- 82% five-year graft survival
- 90% patient survival rate
- 50 ml/min/m2 eGFR

EU Approval* as desensitization treatment as IDEFIRIX®

Addresses the limitations of other modalities

The **first and only** approved drug to enable incompatible kidney transplants

Market access in 75% of the EU transplant market

*IDEFIRIX approved in EEA under conditional approval for kidney transplantation

HANSA BIOPHARMA

Market Access obtained in 14 markets covering markets with 3/4 of transplant volumes in Europe

HTA processes running in 11 countries including Portugal, Switzerland



[1] Annual kidney transplantations 2022. Transplantation data is from Global Observatory on Donation and Transplantation, https://www.transplant-observatory.org/ [Accessed 2023-07-10]

[2] A positive recommendation for pricing and reimbursement of Idefirix® in Spain was published on February 6, 2023, https://www.sanidad.gob.es/profesionales/farmacia/pdf/20230202_ACUERDOS_CIPM_230.pdf

Autoimmunity

Imlifidase may have relevance in several autoimmune diseases where IgG plays an important role in the pathogenesis

+100 autoimmune diseases

- Rapidly progressive glomerulonephritis
- Neurological disorders
- Skin disorders
- Blood disorders

Pivotal Phase 3 trial in anti-GBM disease to evaluate kidney function after 6 months



- 1,200 people affected in US and EU annually
- Standard of care deemed insufficient
- Phase 3 trial 50% enrolled

Catalyst to more IgG mediated conditions



Combination and stand-alone

- Potential autoimmune indications (currently not pursued)
- Clinical programs

*Total disease populations in EU & US, based on prevalence and population data

HANSA BIOPHARMA

Gene Therapy



Imlifidase may enable gene therapy treatment in rare disease patients with pre-existing antibodies

AAVs
the delivery system of most gene therapies

5-70%
patients considered for gene therapy have anti-AAV antibodies

Pre-existing antibodies
excludes patients from trials & treatment

Eliminate antibodies as a pre-treatment to enable gene therapy



- Significant unmet need
- Encouraging pre-clinical data
- Partnership strategy

Global partnerships with gene therapy companies

SAREPTA THERAPEUTICS

- World leader within gene therapy targeted at muscular dystrophies
- High level read out in DMD expected 2024

AskBio

- Early innovator in gene therapy
- Encouraging Ph 1 data presented at ASGCT 2024

GENETHON
CURE THROUGH INNOVATION

- A not-for-profit pioneer in gene therapies
- Preclinical work underway in Crigler-Najjar syndrome

HANSA BIOPHARMA

HNSA-5487 is a next gen enzyme with long and short interval redosing potential

Lower immunogenicity
could apply to diseases where prolonged or intermittent IgG free window is needed

Short interval redosing
create a longer IgG-low period

Long interval redosing
keeps IgG at a low level, potentially leading to greater efficacy vs monotherapy

Encouraging high level Phase 1 study results
single ascending dose in 36 healthy volunteers

- Administration was safe and well tolerated
- Fast and complete cleavage of IgG; PK in line with expectations
- Further analysis and lead indication selection completed in 2024

Potential indication landscape
through two different redosing regimens



Long and short interval redosing could broaden indication universe

Long interval 5487 repeat dosing

Hypothetical model



- Could be used when humoral inhibitors/modulators are too slow
- chronic humoral inhibition can keep the IgG at a low level, potentially leading to greater efficacy vs monotherapy

Short interval 5487 redosing

Hypothetical model



- Short-term treatment in autoimmune diseases
- AAV gene therapy redosing
- HSCT in DSA+ patients
- Repeat dosing of systemic oncolytic virus therapy


HANSA
BIOPHARMA

Continued progress against our key launch metrics led by in-market growth

Market Building

7 - Medical guidelines implemented on a national level in 7 countries

11 - 8 Ongoing HTA processes in 11 countries; most recently in Ireland

Market Access

14 - 10 Market access secured in 14 European markets or 75% of the European transplant market

✓ <u>Eurotransplant:</u> Two patients treated in the ET desensitization program; Patient assessment continues

Patient Identification

36 - 8 Post Approval Study ~72% into completion

Transplant Center Readiness & Use

~50 - 25 ~50 clinics are IDEFIRIX "ready" to treat patients

25 - 15 25 centers with clinical experience in transplantation incl. 17 centers that had repeat usage

Major markets to support growth going forward: France, U.K., Germany, Spain and Italy

Q1 2024 Q1 2023

Systemic gene therapy is an emerging opportunity

with a focus on the potential to correct diseases causing genes in rare monogenic diseases

Rare monogenic diseases
From hundreds of patients to thousands of patients

Size of indication (US & EU)

Preclinical programs with Sarepta, AskBio and Genethon
Ongoing clinical study with Sarepta
Potential gene therapy indications (currently not pursued)



Numbers are estimated based on population and prevalence

1. Rarediseases.org. https://rarediseases.org/rare-diseases/dystrophy-myotonic/[Accessed 2023-06-28]
2. Medlineplus.gov. https://medlineplus.gov/genetics/condition/gaucher-disease/#frequency Accessed 2023-06-20
3. Sandahl TD, Laursen TL, Munk DE, Vilstrup H, Weiss KH, Ott P. The Prevalence of Wilson's Disease: An Update. Hepatology. 2020 Feb;71(2):722-732. doi: 10.1002/hep.30911. Epub 2020 Jan 31. PMID: 31449670.
4. Ghazi A, Grant JA. Hereditary angioedema: epidemiology, management, and role of icatibant. Biologics. 2013;7:103-13. doi: 10.2147/BTT.S27566. Epub 2013 May 3. PMID: 23662043; PMCID: PMC3647445.
5. HillertA, et. al The Genetic Landscape and Epidemiology of Phenylketonuria. Am J Hum Genet. 2020 Aug 6;107(2):234-250. doi: 10.1016/j.ajhg.2020.06.006.Epub 2020 Jul 14. PMID: 32668217; PMCID: PMC7413859.
6. Medlineplus.gov. https://medlineplus.gov/genetics/condition/fabry-disease/#frequency[Accessed: 2023-07-12]
7. Liang, WC., Jong, YJ., Wang, CH. et al. Clinical, pathological, imaging, and genetic characterization in a Taiwanese cohort with limb-girdle muscular dystrophy. Orphanet J Rare Dis 15, 160 (2020). https://doi.org/10.1186/s13023-020-01445-2
8. Rarediseases.org. https://rarediseases.org/rare-diseases/pompe-disease/[Accessed 2023-07-12]
9. Genethon.com, https://www.genethon.com/our-pipeline/crigler-najjar-syndrome/ [Accessed 2023-06-15]
10. GajulaP, Ramalingam K, BhadrashettyD. A rare case of mucopolysaccharidosis: Hunter syndrome. J Nat Sci Biol Med. 2012 Jan;3(1):97-100. doi: 10.4103/0976-9668.95684
11. Rarediseases.org. https://rarediseases.org/rare-diseases/ornithine-transcarbamylase-deficiency/[Accessed 2023-07-12]
12. Crisafulli S, et. Al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020 Jun 5;15(1):141.doi: 10.1186/s13023-020-01430-8. PMID: 32503598; PMCID: PMC7275923.
13. GlobalData[Accessed 2023-12-15]
14. Verhaart, I.E.C., Robertson, A., Wilson, I.J. et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis 12, 124 (2017). https://doi.org/10.1186/s13023-017-0671-8

Global exclusive agreements with three partners in gene therapy

To develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications

Partner	Access to key resources	Indication exclusivity	Collaborative research, development and commercialization
SAREPTA THERAPEUTICS	▪ World leader within gene therapy targeted at muscular dystrophies ▪ Pre-clinical and clinical plan ▪ Regulatory ▪ Promotion ▪ FDA approval for treatment of 4–5-year-old DMD patients	**Duchenne Muscular Dystrophy (DMD)** 1/3,500 to 5,000 male births worldwide	Antibody cleaving enzyme technology ✓ → Preclinical Development ✓ → Clinical Development ✓ → Regulatory Approvals → Commercialization
		Limb-Girdle Muscular Dystrophy Global prevalence of ~1.6 per 100k individuals	Antibody cleaving enzyme technology ✓ → Preclinical Development → Clinical Development → Regulatory Approvals → Commercialization
AskBio	▪ Early innovator in gene therapy ▪ Conducts pre-clinical and clinical trials (Phase 1/2)	**Pompe disease** Affecting ~ 5,000 – 10,000 patients in the US and EU. In addition, 1 in 40,000 births (200 cases) are diagnosed yearly.	Antibody cleaving enzyme technology ✓ → Preclinical Development → Clinical Development Phase 1/2 study (feasibility)
GENETHON CURE THROUGH INNOVATION	▪ A pioneer in the discovery and development of gene therapies ▪ Conducts pre-clinical and clinical trials (Phase 1/2)	**Crigler-Najjar syndrome** Approximately incidence is 0.6-1 case per one million people or 600 patients in Europe and the U.S	Antibody cleaving enzyme technology ✓ → Preclinical Development → Clinical Development Phase 1/2 study (feasibility)

Exclusive option for AskBio to negotiate a potential full development and commercialization agreement

The initial agreement is focused on research and development

The companies will consider a subsequent agreement for commercialization at a later stage

Potential indication universe



*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.
**) In the US a new study has commenced targeting a BLA filing in 2025